NanoBio Receives Grant to Develop an Intranasal Vaccine for RSV

Media contact

Phone:
206-709-3400
Mail:
media@gatesfoundation.org

ANN ARBOR, Mich. -- NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).

RSV is a highly contagious viral disease and is one of the most common causes of bronchiolitis and pneumonia. It is the number one cause of childhood hospitalization both in the United States and around the world. Nearly all children are infected with the virus at least once by the age of 2-3 years. The disease is particularly dangerous for premature babies, children with other health conditions and the elderly. Many children develop persistent pulmonary disease and/or asthma that persists throughout adult life making them susceptible to re-infection as adults. Currently, there are no approved vaccines for RSV.

To read the full press release, visit the NanoBio Corporation web site.

Sign up for The Optimist newsletter

Subscribe to The Optimist to get updates on the latest in global health, gender equality, education, and more. Subscribing and completing your profile is the best way to stay up to date with the Gates Foundation, our partners, events, and other ways to stay connected.